Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI-CPK-1003)

Centre Oscar Lambret

Status: Completed

Conditions: Solid Tumor; Cancer

Treatments: Other: Clinical exam; Biological: CPK dosage

Study type: Observational

Funder types: Other

Identifiers

NCT01248429

TKI-CPK 1003

Details and patient eligibility

About

This study describes the elevation of CPK in patient treated for solid tumors by TKI

Enrollment: 154 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
• Patient examined AND with a routine blood test planned
• Patient informed of procedure for the study who was not opposed to it

Exclusion criteria

• Patient treated for malignant hemopathy
• Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
• Patients with no routine blood laboratory tests planned

Trial design

154 participants in 1 patient group

Patient treated by TKI

Description:

Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week

Treatment:

Other: Clinical exam

Biological: CPK dosage